Ticagrelor-d7 is intended for use as an internal standard for the quantification of ticagrelor by GC- or LC-MS. Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor (Ki = 14 nM; IC50 = 1.8 μM), which is the main receptor responsible for ADP-induced platelet aggregation.1,2 It functions by directly changing the conformation of the P2Y12 receptor to inhibit ADP binding.3 Formulations containing ticagrelor have been used to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome.
1.Zech, G., Hessler, G., Evers, A., et al.Identification of high-affinity P2Y12 antagonists based on a phenylpyrazole glutamic acid piperazine backboneJ. Med. Chem.55(20)8615-8629(2012) 2.Michelson, A.D.Advances in antiplatelet therapyHematology Am. Soc. Hematol. Educ. Program2011(1)62-69(2011) 3.Wallentin, L.P2Y12 inhibitors: Differences in properties and mechanisms of action and potential consequences for clinical useEur. Heart J.30(16)1964-1977(2009)